Scanning and combinatorial library services – Save 20% with code TRY-BXPLIB-20

Join Codex DNA at The World Vaccine Congress

April 18-21, 2022 | WASHINGTON, D.C.

  April 18-21, 2022 | Washington, D.C.

World Vaccine Congress

The World Vaccine Congress is the largest, most established meeting dedicated to vaccines. From basic research to commercial manufacture, this one meeting covers the whole vaccine value chain where science, government and manufacturers all come together to create groundbreaking progress.

More info

Stop by Booth #202 to experience the BioXp system and meet our DNA and mRNA synthesis experts.

Sponsored presentation

WVC DC Day 2 - April 20 @ 15:40

Targeting KRAS mutations in cancer: new mRNA vaccine on the horizon

KRAS is one of the most frequently mutated oncogenes in human cancer, present in about 20% of human cancers. Majority of the KRAS mutation occur at one of the three mutational hotspots: G12, G13 and Q61. In addition, mutations localized to other codons, such as 19, 117 and 146 have been shown to have similar phenotypes as that hotspot mutations. Although KRAS is a critical oncogene, KRAS has long been considered undruggable, and many drug discovery efforts which focused on indirect targeting have been unsuccessful. Only recently specific mutant KRAS inhibitors have been discovered. We designed Pan-Ras mRNA vaccine (mRNA-1521), which covers most of RAS mutation hotspots, for cancer treatment. mRNA-1521 could elicit T cell and B cell responses required for cancer therapy. The tumor inhibition study showed that slower tumor growth in mRNA-1521 vaccinated group when compared to negative control group. At the end of the study, the tumor size and tumor weight of vaccinated group is about 30% less than control group (1000mm3 vs 1500mm3 and 1.5g vs. 2.2g, respectively), indicating that mRNA-1521 vaccine was able to inhibit tumor growth in mouse tumor model.

Presented by:

dong-shen

Dong Shen | Chief Executive Officer & Founder

RNAimmune

Dong Shen, MD, PhD, graduated from Johns Hopkins University School of Medicine, is the founder and President of RNAimmune. Headquartered in Gaithersburg, MD, RNAimmune uses advanced and proprietary delivery platform to develop mRNA-based vaccines and therapeutics, including prophylactic vaccine, tumor vaccine, and therapeutics programs. Dr. Shen received numerous awards in the past. He was the recipient of Johnson & Johnson leadership award in 2018 and innovation award in 2017. All his manuscripts have been published at the most influential journals, such as Science and Nature. The total number of his publication citations is over 20,024.

Contact us

The expertise of our scientists, engineers and supporting teams are at your service! Submit the form below and/or call us at 858.526.3080.

This field is for validation purposes and should be left unchanged.

By clicking Submit, you agree that Codex DNA may use this information to contact you about our programs, products, or services. You may opt out at any time.

Your personal data is handled according to our privacy policy. In addition, if you are located within a distributor territory, you may be contacted directly by them. We never sell your data to anyone.